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g.2012.0Abstract Rheumatoid arthritis (RA) is a multifactorial disorder related to the inﬂammatory
response system with debilitating and painful conditions. Both genetic and environmental factors,
with unknown etiology, play important roles in this disease pathogenesis. Recently, TRAF1/C5
(Tumor Necrosis Factor Receptor-Associated Factor 1/Complement Component 5) polymorphism
associated with increased risk for RA has been studied in different populations worldwide, and
inconsistent results have been obtained. rs10818488 allele is located on TRAF1/C5 intergenic
region, and has been predicted to be functional. A total of 100 sex- and age-matched people includ-
ing RA patients (n= 50) and healthy individuals (n= 50) from Iran have been entered in this study
and genotyped for rs10818488 (A/G) polymorphism, using Polymerase Chain Reaction-Restriction
Fragment Length Polymorphism (PCR-RFLP). In our study, rs10818488 allele was not associated
with risk for RA in Iranian population (p> 0.05, OR = 1.27, 95% CI = 0.72–2.23). Results
revealed that this allele might be population-speciﬁc and not to be associated with their correspond-
ing gene pool. However, further analyses are required to clarify other RA-associated markers in our
community.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1714430564.
(E. Samadian).
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Rheumatoid arthritis (RA) is a multifactorial disorder related
to the inﬂammatory response system and characterized by pro-
gressive joint damage and increased mortality, with aetiologi-
cal wide spectrum of phenotypes. Interactions between both
environmental and genetic contributors confer heterogeneityier B.V. All rights reserved.
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genetic determinants in RA has been improved by the study
of many HLA and non-HLA genes. Among HLA genes, in
all populations worldwide HLA-DRB1 has a pivotal role in
RA symptoms [4], whereas from non-HLA risk factors that
have been found with a lower rate of association, PTP22
[5,6], TRAF1/C5 [7,8], TNFAIP3 [5,9,10], and STAT4 [11]
have been demonstrated as promising RA-correlated markers
[12,13]. TRAF1/C5 region on chromosome 9q33-34, both of
immune response-related genes, has been in recent years iden-
tiﬁed to impact on RA [7,14]. Signiﬁcant depletion of comple-
ment components followed by elevated level of C5a in synovial
ﬂuid of RA patients [15] and resistance to arthritis in C5a-
receptor deﬁcient mice [16,17] as well as linkage studies showed
the involvement of a complement system in RA pathogenesis
[7,18,19]. TRAF1 is a critical adaptor in proinﬂamatory cyto-
kine TNF-alpha signaling cascade as a RA-pathogenic effect-
er. In this cascade, stimulation of TNF-receptor 2 (TNFR2)
induces TRAF2 degradation and inhibits the TNFR1-induced
NF-KB activation. In contrast TRAF1 inhibits TRAF2 degra-
dation; subsequently signal would be changed from apoptosis
toward NF-KB activation and proinﬂamatory responses
[20,21]. However, several population genetic studies also sug-
gested that different single nucleotide polymorphisms (SNPs)
at TRAF1/C5 ﬂanking region has a critical role in RA, but dif-
ferent results have been obtained. rs10818488 in this region is
predicted to be functional and may affect TRAF1 and C5
expression [7]. Although, this variant is known as a RA-
susceptibility, it is not consistent in all populations. Since no
evidence of the relationship between TRAF1/C5 region poly-
morphisms (rs10818488 allele) and RA has been reported in
populations from the west of Asia, we have decided to study
rs10818488 allele and its relation with RA in Iranian
populations.
2. Subjects and methods
2.1. Study population
The subjects enrolled in this study comprised 50 patients with
RA and 50 healthy controls from unrelated families living in
the province of Kermanshah (west of Iran). The diagnosis of
RA was made according to the American Rheumatism Associ-
ation 1987 revised criteria [22]. All participants gave written
informed consent and people with unrelated origin were
excluded.
2.2. Genotyping for rs10818488
Genomic DNA samples of all individuals were isolated from
whole blood collected with anticoagulant (EDTA, 15% w/v),
using a ‘salting out’ method [23]. The forward primer
50-GCA GCA GCA GAA CTA CGT GA 30 and the reverse
primer 50-GCT TGC TGT TGA AAT CCT GAA GG-30 were
used to amplify a 226 bp-intergenic region of the TRAF1/C5
locus. The ampliﬁcation was carried out using the Taq DNA
polymerase (Fermentas). Polymerase chain reaction (PCR)
products were analyzed through electrophoresis on 1.5% aga-
rose gel in reference to a molecular weight marker.
Genotyping for the rs10818488 (A/G) polymorphism was
performed by restriction analysis according to Zervou et al.[25]. Genotypes were scored blindly and analysis of all samples
was repeated twice for checking the accuracy of the results.
2.3. Statistical analysis
In this case-control study, the variant under investigation was
evaluated for deviation from Hardy–Weinberg equilibrium by
comparing observed and expected genotype frequencies by
means of Chi-square test in the control groups. The statistical
difference in genotype distribution and allele frequencies in
both control and case subjects was assessed by using standard
2 · 2 test. Odds ratios (ORs) and conﬁdence intervals (CIs)
were calculated and a p value of 0.05 was determined as
signiﬁcant.3. Results
The RA study group (n= 50) and unrelated healthy controls
(n= 50) were of similar sex and age and consisted of 40 wo-
men and 10 men with 58 ± 5 years (Mean ± SD). Allele and
genotype frequencies of the analyzed samples of the TRAF1/
C5 rs10818488 G/A polymorphism are depicted in the table
below.
Study groups Mutant
Allele A
(%)
Wild type
Allele G
(%)
P Value Odd ratio
(95% CI)
Allele Frequency
RA patients
(n= 100)
46(46) 54(54) > 0.05 1.27
(0.72–2.23)
Controls
(n= 100)
40(40) 60(60)
Genotype frequency G/A or A/A G/G
RA patients
(n= 50)
44 (88) 6 (12) >0.05 1.83
(0.61–5.5)
Controls
(n= 50)
40 (80) 10 (20)Deviation from Hardy–Weinberg equilibrium was not
found with regard to genotypes distribution in the control
group (p> 0.05). We observed that the G/A or A/A genotypes
were not common in RA patients (88%) as compared with
control individuals (80%) and the difference was not statisti-
cally signiﬁcant (p> 0.05). The observed difference was calcu-
lated with a 2 · 2 v2 test. So, it cannot be considered that there
is a relationship between mutant genotypes (G/A or A/A) and
Iranian patients with RA (OR= 1.83, 95% CI = 0.61–5.5).
Patients with RA also did not commonly show the A allele
(46%) compared to controls (40%) (p> 0.05, OR = 1.27,
95% CI = 0.72–2.23). Therefore, it can be regarded that there
is no association between the mutant allele and RA in patients
of Iranian origin. Gel pictures depicted below show G/G, G/A
(Fig. 1.) and A/A (Fig. 2.) genotypes in our study.4. Discussion
Relationships between different candidate genes and RA dis-
ease in different ethnic groups have been recently evaluated
in several studies. Candidate gene approach revealed that the
Figure 1 G/G and G/A genotypes are depicted; Lane 1: 100-bp
Ladder, Lane 2: G/G (G allele digested into 169- and 57-bp
fragments), Lane 3: G/A (digested G and undigested A allele).
Figure 2 A/A genotype is depicted; Lane 1: 100-bp Ladder, Lane
2 and 3: undigested A allele (226-bp fragment).
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susceptibility to RA in Dutch [7] and Spanish (Kureeman
et al., data not reported) populations. Although, a meta-
analysis [24] and association studies in Creten [25] Egyptian
ethnicities [26] and western European white individuals from
‘‘trio’’ families [27] conﬁrmed this ﬁnding. However, similar
observations were not found in Swedish [5] and Colombian
[28] populations, these inconsistencies were also reported in
Asians. Mutated A allele of rs10818488 is not associated with
increasing risk of RA in Korean population [29] though;
Nishimoto et al. observed that wild type (G) allele of
rs10818488 was modestly associated with RA in Japanese
[30]. Interestingly, other TRAF1/C5 polymorphic alleles such
as rs3761847 have been shown to be signiﬁcantly associated
with RA in Korean [29] and Han Chinese [31] Asians. Our
study provides evidence that there is no relation between
rs10818488 and RA in Iranian population. Therefore,
rs10818488 might not be a genius allele related to RA in Asians
and also, there are distinct population speciﬁc differences in
the prevalence of this allele. The point should not to be
forgotten that the Iranian population is composed of different
ethnic groups, so, identifying alleles that have lower frequency
in this population is hardly possible. It must be ﬂagged out
that the gene pool in our studied population may speciﬁcally
have other RA-susceptibility alleles because of migration,recombination and so on. Thus, further investigations are
needed to prove our study.
These challenging ﬁndings and increased TRAF1 expression
level in phorbol myristate acetate-stimulated lymphoblastoid
cell lines [30], in most recent studies, may reﬂect epigenetic
effects of rs10818488 allele in different populations. This allele is
located in TRAF1/C5 intergenic region and predicted to be a
putative binding site for transcription factor EP300 [7]. EP300
plays important roles in vast biological processes, including cell
proliferation and differentiation [32]. Moreover, rs10818488
may regulate the expression of both neighbour genes, TRAF1
andC5 that are involved in proinﬂamatory TNFalpha signaling
cascade, and as a result inﬂuencing RA pathogenesis.
5. Conclusion
Although, many RA-associated genes (about 31 genes) have
been reported by now [5,7–11,33–35], many efforts remained
66 E. Samadian et al.to be attempted to make a gene map for these markers. At the
end we cannot turn a blind eye on environmental factors in RA
development and progression.Acknowledgments
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